Drug approval: Crizotinib in unresectable or refractory ALK-positive pediatric inflammatory myofibroblastic tumors

被引：0
作者：
Tenaillon, Anne [1 ]
Orbach, Daniel [1 ]
机构：
[1] Inst Curie, Ctr Integre Soins & Rech Oncol Enfant Adolescent &, 26 rue Ulm, F-75005 Paris, France
来源：
BULLETIN DU CANCER | 2023年 / 110卷 / 04期
关键词：
Inflammatory myofibroblastic tumor; Targeted therapy; ALK-positive; Crizotinib; Children;
D O I：
10.1016/j.bulcan.2022.12.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：248 / 249
页数：2
相关论文
共 50 条
  • [1] Two-year crizotinib monotherapy induced durable complete response of pediatric ALK-positive inflammatory myofibroblastic tumor
    Kaino, Akira
    Niizuma, Hidetaka
    Katayama, Saori
    Irie, Masahiro
    Nakano, Tomohiro
    Sato, Daichi
    Saito, Tsuyoshi
    Kato, Shunsuke
    Suehara, Yoshiyuki
    Sasahara, Yoji
    Kikuchi, Atsuo
    PEDIATRIC BLOOD & CANCER, 2023, 70 (08)
  • [2] Drug approval: Crizotinib for relapsed or refractory, ALK-positive, systemic anaplastic large cell lymphoma in pediatrics
    Meurillon, Roxane
    Leruste, Amaury
    BULLETIN DU CANCER, 2023, 110 (03) : 250 - 251
  • [3] Use of crizotinib for refractory ALK-positive lymphomas
    Shelikhova, L. N.
    Fominykh, V. V.
    Abramov, D. S.
    Myakova, N. V.
    Maschan, M. A.
    Maschan, A. A.
    TERAPEVTICHESKII ARKHIV, 2017, 89 (07) : 51 - 56
  • [4] Podcast on Emerging Treatment Options for Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumors
    Lowe, Eric
    Mosse, Yael P.
    ONCOLOGY AND THERAPY, 2024, 12 (02) : 247 - 255
  • [5] Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large celllymphoma
    Knoerr, Fabian
    Schellekens, Kim P. J.
    Schoot, Reineke A.
    Landman-Parker, Judith
    Teltschik, Heiko-Manuel
    Foerster, Jan
    Riquelme, Amambay
    Huitema, Alwin D. R.
    van Eijkelenburg, Natasha K. A.
    Beishuizen, Auke
    Zwaan, C. Michel
    Woessmann, Wilhelm
    van der Lugt, Jasper
    HAEMATOLOGICA, 2023, 108 (05) : 1442 - 1446
  • [6] Population modeling analyses of crizotinib in pediatric patients with ALK-positive advanced cancers
    Jerry, Li
    Swan, Lin
    Dana, Nickens
    Balis, Frank M.
    Greengard, Emily
    Xu, Huiping
    PEDIATRIC BLOOD & CANCER, 2024, 71 (09)
  • [7] Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib
    Ganesan, Prasanth
    Joshua, Thanda
    Sundersingh, Shirley
    Sagar, Tenali Gnana
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2018, 34 (02) : 353 - 354
  • [8] Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
    Ogata, Misato
    Hatachi, Yukimasa
    Ogata, Takatsugu
    Satake, Hironaga
    Imai, Yukihiro
    Yasui, Hisateru
    INTERNAL MEDICINE, 2019, 58 (07) : 1029 - 1032
  • [9] Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib
    Prasanth Ganesan
    Thanda Joshua
    Shirley Sundersingh
    Tenali Gnana Sagar
    Indian Journal of Hematology and Blood Transfusion, 2018, 34 : 353 - 354
  • [10] ALK-Positive Inflammatory Myofibroblastic Tumor of the Abdomen With Widespread Microscopic Multifocality
    Lorenzi, Luisa
    Cigognetti, Marta
    Medicina, Daniela
    Pellegrini, Vilma
    Balzarini, Piera
    Cestari, Renzo
    Facchetti, Fabio
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2014, 22 (07) : 640 - 644
12345